MedTrace Logo

Effects of DHA in Patients With Multiple Sclerosis

NCT07346703 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-16

No results posted yet for this study

Summary

This clinical trial will investigate the effects of combining therapeutic exercise with DHA supplementation in 100 patients with multiple sclerosis using a randomized controlled design. Participants, diagnosed according to the McDonald criteria, will undergo functional, cognitive, fatigue, and quality-of-life assessments through tools such as the EDSS, BRB-N, MFIS, EVA-f, and MSQoL-54. Physiological evaluations will include infrared thermography, isokinetic strength testing, perceived exertion (Modified Borg Scale), balance (Timed Up and Go), lower-limb power (Sit-to-Stand app), and handgrip strength. The study hypothesizes that this combined intervention will improve motor function, cognition, fatigue management, and overall quality of life by enhancing neuromuscular activation and metabolic efficiency.

Conditions

  • Multiple Sclerosis
  • Performance Enhancement
  • Supplemental Nutrition Assistance Program Education
  • Strength Outcomes
  • Function Improvement
  • Intervention Study

Interventions

DIETARY_SUPPLEMENT

Docosahexaenoic Acid (DHA) Dietary Supplement

Subjects will take 2 g of DHA per day for 3 months.

DIETARY_SUPPLEMENT

Docosahexaenoic Acid (DHA) Dietary Supplement

Subjects will take 2 g of DHA per day + therapeutic exercise (3 times a week) for 3 months.

DIETARY_SUPPLEMENT

Sunflower Oil

Subjects will take 2 g of placebo (sunflower oil) per day for 3 months.

DIETARY_SUPPLEMENT

Sunflower Oil

Subjects will take 2 g of placebo per day + therapeutic exercise (3 times a week) for 3 months.

Sponsors & Collaborators

  • Francisco Javier Martínez Noguera

    lead OTHER

Principal Investigators

  • Francisco Javier Martínez Noguera, Researcher-PhD · Universidad Católica San Antonio de Murcia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2026-06-30
Completion
2026-07-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07346703 on ClinicalTrials.gov